Onconova Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets, December 31, 2023 and 2022
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2023 · 2022 | ||||||
| Assets · · · · · | ||||||
| Current assets: | | | | | | |
| Cash and cash equivalents | | $20,821,000 | | $38,757,000 | ||
| Receivables | | 18,000 | | 29,000 | ||
| Prepaid expenses and other current assets | | 1,821,000 | | 561,000 | ||
| Total current assets | | 22,660,000 | | 39,347,000 | ||
| Property and equipment, net | | 22,000 | | 24,000 | ||
| Other non-current assets | | 1,000 | | 1,000 | ||
| Total assets | | $22,683,000 | | $39,372,000 | ||
| Liabilities and stockholders’ equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $5,619,000 | | $3,860,000 | ||
| Accrued expenses and other current liabilities | | 3,375,000 | | 3,960,000 | ||
| Deferred revenue | | 226,000 | | 226,000 | ||
| Total current liabilities | | 9,220,000 | | 8,046,000 | ||
| Deferred revenue, non-current | | 2,791,000 | | 3,017,000 | ||
| Total liabilities | | 12,011,000 | | 11,063,000 | ||
| | | | | | | |
| Commitments and contingencies | | | | | | |
| | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, $0.01 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2023 and December 31, 2022 | | — | | — | ||
| Common stock, $0.01 par value, 125,000,000 shares authorized, 21,003,409 and 20,925,992 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | | 210,000 | | 209,000 | ||
| Additional paid in capital | | 493,116,000 | | 491,816,000 | ||
| Accumulated deficit | | (482,631,000) | | (463,683,000) | ||
| Accumulated other comprehensive loss | | (23,000) | | (33,000) | ||
| Total stockholders’ equity | | 10,672,000 | | 28,309,000 | ||
| Total liabilities and stockholders’ equity | | $22,683,000 | | $39,372,000 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.